AroKor Holdings

Korro Bio, formerly known as AroKor Holdings, is a biopharmaceutical company pioneering the development of RNA editing therapies to treat both rare and common diseases. The company's proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform harnesses the body's natural ADAR enzymes to perform precise, single-base RNA editing. This approach allows for the correction of pathogenic mutations or the modulation of protein function without the risks associated with permanent DNA genome editing. Korro Bio's lead candidate, KRRO-110, is an IND-enabling program designed to treat Alpha-1 Antitrypsin Deficiency by restoring functional protein levels. The company's broader pipeline includes discovery-stage programs targeting high-value indications in the central nervous system, liver, and cardiometabolic health.